The ADA 2025 presentations will cover: Phase 1 Trial Results for HM15275, Robust anti-obesity effect and mechanistic insights of HM15275 in animal models of obesity, Mechanistic insights into HM15275s improved quality of weight loss compared to tirzepatide (Zepbound), Weight loss and differentiated body composition improvement effects of HM17321, Glycemic control improvement observed with HM17321, and Synergistic effects on body composition improvement when combining HM15275 and HM17321 A large delegation from Hanmis R&D Center will attend ADA 2025 to present poster sessions showcasing the companys novel therapeutic approaches in obesity treatment and to explore potential collaborations with leading global pharmaceutical companies
Patients who typically drink very little or who run chronically low urine volumes may also need to be especially attentive when starting a GLP1 therapy
Companies like Roche, AbbVie, and Amgen treat a core therapeutic protein as a platform and continuously file indication expansion patents as clinical programs identify new patient populations
If you are taking pantoprazole and still experiencing severe symptoms like difficulty swallowing, persistent vomiting, or unexplained weight loss that feels rapid and unhealthy, you should seek medical attention
10.1016/0960-0760(95)00093-F 68
Compression therapy is the cornerstone of long-term management
